Skip to Content
Merck
CN

72310

Nicotinic acid

purum, ≥99.0% (HPLC)

Synonym(s):

3-Picolinic acid, Niacin, Pellagra preventive factor, Pyridine-3-carboxylic acid, Vitamin B3

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C6H5NO2
CAS Number:
Molecular Weight:
123.11
EC Number:
200-441-0
UNSPSC Code:
12352200
PubChem Substance ID:
Beilstein/REAXYS Number:
109591
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

biological source

synthetic

grade

purum

assay

≥99.0% (HPLC)

form

powder

color

colorless to white

mp

233-238 °C, 236-239 °C (lit.)

SMILES string

OC(=O)c1cccnc1

InChI

1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)

InChI key

PVNIIMVLHYAWGP-UHFFFAOYSA-N

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Eye Irrit. 2

Storage Class

11 - Combustible Solids

wgk

WGK 1

flash_point_f

379.4 °F - closed cup

flash_point_c

193 °C - closed cup

ppe

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

新产品

This item has


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Koon K Teo et al.
Stroke, 44(10), 2688-2693 (2013-07-25)
In Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial, addition of extended-release niacin (ERN) to simvastatin in participants with established cardiovascular disease, low high-density lipoprotein cholesterol, and high triglycerides had no incremental
John R Guyton et al.
Journal of the American College of Cardiology, 62(17), 1580-1584 (2013-08-07)
This study sought to examine the relationship between niacin treatment, lipoproteins, and cardiovascular (CV) outcomes in this secondary analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial. During a
Martina Lukasova et al.
Trends in pharmacological sciences, 32(12), 700-707 (2011-09-29)
Nicotinic acid (niacin) has been used for decades to prevent and treat atherosclerosis. The well-documented antiatherogenic activity is believed to result from its antidyslipidemic effects, which are accompanied by unwanted effects, especially a flush. There has been renewed interest in
Amandine Girousse et al.
PLoS biology, 11(2), e1001485-e1001485 (2013-02-23)
When energy is needed, white adipose tissue (WAT) provides fatty acids (FAs) for use in peripheral tissues via stimulation of fat cell lipolysis. FAs have been postulated to play a critical role in the development of obesity-induced insulin resistance, a
Mattijs M Heemskerk et al.
American journal of physiology. Endocrinology and metabolism, 306(7), E808-E813 (2014-01-30)
The lipid-lowering effect of niacin has been attributed to the inhibition of cAMP production in adipocytes, thereby inhibiting intracellular lipolysis and release of nonesterified fatty acids (NEFA) to the circulation. However, long-term niacin treatment leads to a normalization of plasma

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service